Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
293
datasets available to search
ShareScore release 0.9.0
Dataset results
293 results for “PARP”
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor
ClinicalTrials.gov study NCT01123876. IPD Sharing: Not stated. Countries: 2. Publications: 2.
Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer
ClinicalTrials.gov study NCT06201234. IPD Sharing: YES. Countries: 1. Publications: 4.
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel
ClinicalTrials.gov study NCT00516724. IPD Sharing: YES. Countries: 3. Publications: 3.
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)
ClinicalTrials.gov study NCT06441747. IPD Sharing: NO. Countries: 1. Publications: 0.
Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor
ClinicalTrials.gov study NCT04734665. IPD Sharing: NO. Countries: 1. Publications: 1.
Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer
ClinicalTrials.gov study NCT03083288. IPD Sharing: NO. Countries: 1. Publications: 1.
Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study
ClinicalTrials.gov study NCT06603506. IPD Sharing: NO. Countries: 1. Publications: 1.
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
ClinicalTrials.gov study NCT05498272. IPD Sharing: NO. Countries: 1. Publications: 1.
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
ClinicalTrials.gov study NCT01623349. IPD Sharing: Not stated. Countries: 1. Publications: 4.
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination
ClinicalTrials.gov study NCT01618136. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer
ClinicalTrials.gov study NCT00515866. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN)
ClinicalTrials.gov study NCT01788332. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance
ClinicalTrials.gov study NCT05704621. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)
ClinicalTrials.gov study NCT00516373. IPD Sharing: YES. Countries: 4. Publications: 3.
A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer
ClinicalTrials.gov study NCT00813956. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention
ClinicalTrials.gov study NCT00271765. IPD Sharing: Not stated. Countries: 2. Publications: 5.
Myelodysplastic Syndrome and Acute Myeloid Leukemia Related to PARP Inhibitors (MyeloRIB)
ClinicalTrials.gov study NCT04326023. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment
ClinicalTrials.gov study NCT05407584. IPD Sharing: NO. Countries: 1. Publications: 1.
Structural dynamics of DNA strand break sensing by PARP-1 at a single-molecule level
Open the record for dataset details and reuse information.
ROS-Specific Huntingtin Interactions: Testing PARP activity in HD patient fibroblasts
<p>Comparison of nuclear PAR levels in wild type and HD (TruHD) fibroblasts in response to a PARP inhibitor concentration gradient (as a measure of PARP activity).</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.